• Sartorius

Cancer drugs that harness the power of the patient’s immune system have altered the paradigm of cancer care in the past few years. Antibody-based therapies against specific cell surface targets can directly modulate the activity of T cells, reawakening their ability to bind to and kill cancer cells. CD3-targeted bispecific antibodies bring T cells and tumor targets in close proximity, facilitating T cell mediated killing.
Read more...